Transplant Genomics Inc, Product Pipeline Analysis: 2019 Update – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Transplant Genomics Inc – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.


Transplant Genomics Inc (TGI) is a part of Eurofins Scientific., is a biotech company. It carries out performing organ transplantation using non-invasive serial monitoring under the guidance of genomics. It aims in detecting early signs of graft injury by conducting molecular diagnostic tests, enabling in differentiating among various actionable causes and also enabling optimizing the therapy. Transplant Genomics carries out the transplantation of organs such as the kidney, liver, lungs, pancreas, and intestines through genomics supervision. The company has its operational presence in the US. TGI is headquartered in Mansfield, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Transplant Genomics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

  • Transplant Genomics Inc Company Overview
  • Transplant Genomics Inc Company Snapshot
  • Transplant Genomics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Transplant Genomics Inc – Pipeline Analysis Overview
  • Transplant Genomics Inc – Key Facts
  • Transplant Genomics Inc – Major Products and Services
  • Transplant Genomics Inc Pipeline Products by Development Stage
  • Transplant Genomics Inc Ongoing Clinical Trials by Trial Status
  • Transplant Genomics Inc Pipeline Products Overview
  • Diagnostic Test – Heart Transplantation
  • Diagnostic Test – Heart Transplantation Product Overview
  • Diagnostic Test – Liver Transplantation
  • Tissue Test
  • TruGraf Blood Test
  • TruGraf Blood Test Clinical Trial
  • TruGraf v2
  • Transplant Genomics Inc – Key Competitors
  • Transplant Genomics Inc – Key Employees
  • Transplant Genomics Inc – Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • Transplant Genomics Inc, Recent Developments
  • Oct 29, 2019: Transplant Genomics founders awarded US patent covering detection of Silent sub-clinical rejection in stable kidney transplant recipients
  • Oct 11, 2019: Transplant Genomics confirms TruGraf will receive medicare coverage effective November 25, 2019
  • Aug 21, 2019: Viracor Eurofins collaborates with Northwestern University Comprehensive Transplant Center on specialized kidney transplant diagnostic
  • Mar 29, 2019: Medicare issues draft Local Coverage Determination (LCD) for Transplant Genomics’ TruGraf Blood Test as alternative to surveillance biopsies
  • Feb 26, 2019: Multi-Center Studies Demonstrate Clinical Utility of TruGraf as First Blood Test Able to Rule Out Silent Rejection in Stable Kidney Transplant Recipients
  • Aug 09, 2018: First blood test to confirm stability by ruling out silent rejection in kidney transplant recipients with stable renal function
  • Jun 12, 2018: Studies Presented at American Transplant Congress Support Clinical Utility of TGI’s TruGraf Tests for Management of Kidney Transplant Recipients
  • Nov 28, 2017: Clinical Utility Study Indicates Potential for TruGraf Test to Replace Surveillance Biopsies in Kidney Transplant Recipients with Stable Renal Function
  • Oct 24, 2017: Study Shows TruGraf Blood Test Enables Non-invasive Detection of Immune Quiescent Kidney Transplant Recipients
  • May 01, 2017: Genomic Signature for Predicting Acute Rejection in Liver Transplant Patients to be Presented at the American Transplant Congress
  • Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

Companies Mentioned

  • CytImmune Sciences Inc
  • Gift of Life Donor Program

For more information about this company profile visit https://www.researchandmarkets.com/r/o7ngrq



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.